Brokerages Set Kura Oncology, Inc. (NASDAQ:KURA) PT at $24.67

Shares of Kura Oncology, Inc. (NASDAQ:KURA) have earned a consensus rating of “Moderate Buy” from the fifteen brokerages that are presently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and ten have given a buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $24.6667.

A number of equities analysts have weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $40.00 price objective on shares of Kura Oncology in a research report on Monday, October 20th. Guggenheim began coverage on Kura Oncology in a research note on Thursday, September 4th. They set a “neutral” rating for the company. Wall Street Zen upgraded Kura Oncology from a “sell” rating to a “hold” rating in a research note on Sunday, August 17th. Wedbush restated an “outperform” rating and set a $36.00 target price on shares of Kura Oncology in a research note on Monday, October 20th. Finally, JMP Securities restated a “market outperform” rating and set a $24.00 target price on shares of Kura Oncology in a research note on Monday, October 20th.

Kura Oncology Stock Down 4.8%

Shares of Kura Oncology stock opened at $10.51 on Friday. The company has a fifty day moving average price of $8.82 and a 200 day moving average price of $7.10. The company has a current ratio of 6.16, a quick ratio of 6.16 and a debt-to-equity ratio of 0.02. Kura Oncology has a twelve month low of $5.41 and a twelve month high of $19.73. The stock has a market cap of $912.27 million, a price-to-earnings ratio of -4.65 and a beta of 0.32.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.75) earnings per share for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.90). The company had revenue of $15.29 million for the quarter, compared to analysts’ expectations of $64.95 million. Equities research analysts forecast that Kura Oncology will post -2.44 earnings per share for the current fiscal year.

Insider Activity at Kura Oncology

In other news, insider Mollie Leoni sold 12,314 shares of the stock in a transaction dated Monday, September 29th. The shares were sold at an average price of $8.94, for a total transaction of $110,087.16. Following the transaction, the insider owned 158,439 shares of the company’s stock, valued at approximately $1,416,444.66. This trade represents a 7.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Kathleen Ford sold 6,892 shares of the stock in a transaction dated Monday, September 29th. The stock was sold at an average price of $8.94, for a total transaction of $61,614.48. Following the transaction, the chief operating officer directly owned 63,375 shares in the company, valued at $566,572.50. The trade was a 9.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 78,058 shares of company stock valued at $697,839. 6.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Kura Oncology

Several large investors have recently modified their holdings of KURA. BVF Inc. IL lifted its position in shares of Kura Oncology by 202.0% during the first quarter. BVF Inc. IL now owns 7,754,129 shares of the company’s stock worth $51,177,000 after purchasing an additional 5,186,660 shares during the last quarter. EcoR1 Capital LLC lifted its position in shares of Kura Oncology by 59.1% during the second quarter. EcoR1 Capital LLC now owns 4,200,000 shares of the company’s stock worth $24,234,000 after purchasing an additional 1,559,702 shares during the last quarter. Armistice Capital LLC raised its stake in Kura Oncology by 13.3% during the first quarter. Armistice Capital LLC now owns 6,572,000 shares of the company’s stock worth $43,375,000 after acquiring an additional 772,000 shares during the period. Qube Research & Technologies Ltd raised its stake in Kura Oncology by 63.0% during the second quarter. Qube Research & Technologies Ltd now owns 1,911,886 shares of the company’s stock worth $11,032,000 after acquiring an additional 738,761 shares during the period. Finally, AQR Capital Management LLC raised its stake in Kura Oncology by 407.8% during the first quarter. AQR Capital Management LLC now owns 760,332 shares of the company’s stock worth $5,018,000 after acquiring an additional 610,604 shares during the period.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.